Dominique Bluteau

Paris, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

ZMAT3 alleviates cell death in Fanconi anemia via adaptation of sphingolipid metabolism.

ZMAT3 alleviates cell death in Fanconi anemia via adaptation of sphingolipid metabolism.

Journal: Science advances
Published: July 31, 2026

Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial.

Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 08, 2025

MDM4 overexpression alleviates developmental and hematopoietic defects in Fancg deficient mice.

MDM4 overexpression alleviates developmental and hematopoietic defects in Fancg deficient mice.

Journal: Leukemia
Published: July 29, 2024

From normal hematopoiesis to malignancies: Highlights from the 2021 Meeting of the Club Hematopoiesis and Oncogenesis.

From normal hematopoiesis to malignancies: Highlights from the 2021 Meeting of the Club Hematopoiesis and Oncogenesis.

Journal: Bulletin du cancer
Published: November 16, 2022

Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia.

Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia.

Journal: Cell stem cell
Published: April 22, 2022

Downregulation of TREM-like transcript-1 and collagen receptor α2 subunit, two novel RUNX1-targets, contributes to platelet dysfunction in familial platelet disorder with predisposition to acute myelogenous leukemia.

Downregulation of TREM-like transcript-1 and collagen receptor α2 subunit, two novel RUNX1-targets, contributes to platelet dysfunction in familial platelet disorder with predisposition to acute myelogenous leukemia.

Journal: Haematologica
Published: January 20, 2018

Biallelic inactivation of REV7 is associated with Fanconi anemia.

Biallelic inactivation of REV7 is associated with Fanconi anemia.

Journal: The Journal of clinical investigation
Published: March 02, 2017

Biallelic truncating FANCM mutations cause early-onset cancer but not Fanconi anemia.

Biallelic truncating FANCM mutations cause early-onset cancer but not Fanconi anemia.

Journal: Genetics in medicine : official journal of the American College of Medical Genetics
Published: February 02, 2017

Biallelic inactivation of REV7 is associated with Fanconi anemia.

Biallelic inactivation of REV7 is associated with Fanconi anemia.

Journal: The Journal of clinical investigation
Published: April 12, 2016

Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia.

Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia.

Journal: Blood
Published: December 11, 2014

p19 INK4d controls hematopoietic stem cells in a cell-autonomous manner during genotoxic stress and through the microenvironment during aging.

p19 INK4d controls hematopoietic stem cells in a cell-autonomous manner during genotoxic stress and through the microenvironment during aging.

Journal: Stem cell reports
Published: April 24, 2014

Mechanisms underlying platelet function defect in a pedigree with familial platelet disorder with a predisposition to acute myelogenous leukemia: potential role for candidate RUNX1 targets.

Mechanisms underlying platelet function defect in a pedigree with familial platelet disorder with a predisposition to acute myelogenous leukemia: potential role for candidate RUNX1 targets.

Journal: Journal of thrombosis and haemostasis : JTH
Published: December 09, 2013
Showing 1-12 of 16

Last Updated: 09/26/2026